SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)
Clin. transl. oncol. (Print)
; 25(9): 2749-2758, sept. 2023. ilus, tab
Artigo
em Inglês
| IBECS
| ID: ibc-224138
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Diffuse large B-cell lymphoma is the most frequent histological subtype of NHL and the paradigm for the management of aggressive lymphoma. An excisional or incisional lymph node biopsy evaluated by an experienced hemopathologist is recommended to establish the diagnosis. Twenty years following its introduction, R-CHOP remains the standard first-line treatment. No modification of this scheme (increased chemotherapy dose intensity, new monoclonal antibodies, or the addition of immunomodulators or anti-target agents) has significatively improved the clinical outcomes, whereas therapy for recurrence or progression is evolving rapidly. The irruption of CART cells, polatuzumab vedotin, tafasitamab, and CD20/CD3 bispecific antibodies are changing the natural history of relapsed patients and will challenge R-CHOP as the benchmark for newly diagnosed patients (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Linfoma Difuso de Grandes Células B
Limite:
Humanos
País/Região como assunto:
Europa
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2023
Tipo de documento:
Artigo
Instituição/País de afiliação:
Complejo Hospitalario Universitario/Spain
/
Hospital Universitari i Politècnic La Fe/Spain
/
Hospital Universitario Puerta de Hierro/Spain
/
Hospital Universitario San Cecilio/Spain
/
Hospital Universitario Virgen de la Macarena/Spain
/
Hospital Universitario de Canarias/Spain
/
IBIMA/Spain
/
Institute for Health and Biomedical Research (ISABIAL)/Spain
/
URV/Spain